BridgeBio Pharma Inventory 2018-2024 | BBIO

BridgeBio Pharma inventory from 2018 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • BridgeBio Pharma inventory for the quarter ending June 30, 2024 was $M, a NAN% increase year-over-year.
  • BridgeBio Pharma inventory for 2023 was $0B, a NAN% decline from 2022.
  • BridgeBio Pharma inventory for 2022 was $0B, a NAN% decline from 2021.
  • BridgeBio Pharma inventory for 2021 was $0B, a NAN% decline from 2020.
BridgeBio Pharma Annual Inventory
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
BridgeBio Pharma Quarterly Inventory
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.028B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.837B 6.73
Dr Reddy's Laboratories (RDY) India $13.111B 19.64
Bausch Health Cos (BHC) Canada $2.902B 2.19
Amphastar Pharmaceuticals (AMPH) United States $2.394B 13.40
Supernus Pharmaceuticals (SUPN) United States $1.753B 353.56
Taysha Gene Therapies (TSHA) United States $0.441B 71.67
Personalis (PSNL) United States $0.305B 0.00
Assembly Biosciences (ASMB) United States $0.123B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00